Ascendis Pharma Stock Slips Despite Positive European Opinion for Already-Approved YUVIWEL
ASND shares closed down 0.6% after a positive European opinion for YUVIWEL, highlighting how investors distinguish fresh catalysts from priced-in news…
Opus Genetics Wins FDA Approval for Presbyopia Treatment: What IRD Investors Should Watch Next
Opus Genetics received FDA approval for Phentolamine Ophthalmic Solution, creating a potential catalyst as investors assess commercialization and pipe…
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Omeros Stock Breaks Key Support After Second EU Rejection of Narsoplimab
Omeros shares fell below key support after the EMA rejected narsoplimab again, highlighting the split between US approva…
Pfizer's Expanded TUKYSA Approval Strengthens Its Breast Cancer Turnaround Case
TUKYSA’s expanded FDA approval may strengthen Pfizer’s oncology franchise and support its post-pandemic revenue diversif…
Merck and Moderna’s Phase 3 Cancer Vaccine Win Raises Stakes for mRNA Oncology
Merck and Moderna’s positive Phase 3 cancer-vaccine results strengthen the case for mRNA-immunotherapy combinations and …
Halozyme’s $130 Price Target Reiterated After Positive Takeda Trial Data
H.C. Wainwright reiterated its Buy rating and $130 price target for Nasdaq-listed Halozyme after positive Takeda trial r…
FDA Approval Expands Enspryng’s Thyroid Eye Disease Opportunity for Roche-Backed Genentech
The FDA approved Enspryng for thyroid eye disease, giving Genentech and Roche a potential new avenue for specialty pharm…
Proofpoint's $6.3 Billion Varonis Deal Puts Cybersecurity M&A and Arbitrage in Focus
Proofpoint’s $6.3 billion all-cash deal for Varonis puts the $49.75 offer, merger spreads and cybersecurity consolidatio…
Potential J&J Orthopedics Spinoff Puts Conglomerate Strategy and Valuation in Focus
A reported J&J plan to spin out its hips-and-knees unit could reshape the valuation and capital-allocation debate around…
Galderma’s $1.5 Billion ZO Skin Health Purchase Signals Continued Aesthetics Consolidation
Galderma’s $1.5 billion cash acquisition of ZO Skin Health highlights consolidation in dermatology and a notable healthc…
Labcorp’s $872 Million BioReference Deal Puts Diagnostics M&A in Focus
Labcorp’s agreement to acquire select BioReference assets from OPKO highlights diagnostics consolidation, valuation ques…